Patents Assigned to Xanthus Life Sciences, Inc.
-
Patent number: 6989390Abstract: Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): R1 is —(CH2)nN+HR3R4 X? or R1 is —(CH2)nN+HR3R4 X? or —(CH2)nNR3R4 when R2 is —N+HR6R7. R2 is —OR5, halogen, —NR6R7, —N+HR6R7 X?? sulphonic acid, nitro, —NR5COOR5, —NR5COR5 or —OCOR5; R3 and R4 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; each R5 is independently —H or a C1-C4 alkyl group; R6 and R7 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; n is an integer from 0-3; and X? is the carboxylate anion of an organic carboxylic acid compound. Also disclosed are methods of preparing certain compounds represented by Structural Formula (I).Type: GrantFiled: October 20, 2003Date of Patent: January 24, 2006Assignee: Xanthus Life Sciences, Inc.Inventors: Alfred M. Ajami, David O. Barlow
-
Publication number: 20050239816Abstract: Disclosed are organic hydroxy acid salts of amonafide: Also disclosed are methods of preparing salts of amonafide and method of treating subjects suffering from cancer.Type: ApplicationFiled: June 29, 2005Publication date: October 27, 2005Applicant: Xanthus Life Sciences, Inc.Inventors: Alfred Ajami, David Barlow
-
Publication number: 20050059738Abstract: A therapeutic composition comprising an alkyl, aralkyl, alkoxyalkyl or carboxyalkyl ester of 2ketoalkanoic acid and a component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is disclosed. The composition of the invention further comprises a pharmaceutically acceptable carier vehicle in which the enol resonance form of the ester is stabilized at physiological pH values. Formulations containing the compositions of the invention permit the successful use of 2-ketoalkanoic acid esters, e.g., pyruvic acid esters, to treat, e.g., is chemic events, shock, organ reanimation, resuscitation and other recognized pyruvate-effective treatments. The compositions of the inventions are also useful in a process for preserving organ parts, organs or limbs removed from a living mammal and in need of preservation, e.g., for later transplantation to an organ recipient.Type: ApplicationFiled: September 23, 2004Publication date: March 17, 2005Applicants: Xanthus Life Sciences, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Alfred Ajami, Carrie Sims, Mitchell Fink
-
Patent number: 6846842Abstract: A therapeutic composition comprising an alkyl, aralkyl, alkoxyalkyl or carboxyalkyl ester of 2-ketoalkanoic acid and a component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is disclosed. The composition of the invention further comprises a pharmceutically acceptable carier vehicle in which the enol resonance form of the ester is stabilized at physiological pH values. Formulations containing the compositions of the invention permit the successful use of 2-ketoalkanoic acid esters, e.g., pyruvic acid esters, to treat, e.g., ischemic events, shock, organ reanimation, resuscitation and other recognized pyruvate-effective treatments. The compositions of the inventions are also useful in a process for preserving organ parts, organs or limbs removed from a living mammal and in need of preservation, e.g., for later transplantation to an organ recipient.Type: GrantFiled: April 4, 2002Date of Patent: January 25, 2005Assignees: Beth Israel Deconess Medical Center, Inc., Xanthus Life Sciences, Inc.Inventors: Alfred M. Ajami, Carrie A. Sims, Mitchell P. Fink
-
Publication number: 20040132763Abstract: Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): 1Type: ApplicationFiled: October 20, 2003Publication date: July 8, 2004Applicant: Xanthus Life Sciences, Inc.Inventors: Alfred M. Ajami, David O. Barlow
-
Publication number: 20040101477Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with anesthetics.Type: ApplicationFiled: November 27, 2002Publication date: May 27, 2004Applicant: Xanthus Life Sciences, Inc.Inventor: Brian Leyland-Jones
-
Publication number: 20040084867Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with anticoagulants.Type: ApplicationFiled: June 27, 2003Publication date: May 6, 2004Applicant: Xanthus Life Sciences, Inc.Inventor: Brian Leyland-Jones
-
Patent number: 6693198Abstract: Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): R1 is —(CH2)nN+HR3R4 X− or R1 is —(CH2)nN+HR3R4 X− or —(CH2)nNR3R4 when R2 is —N+HR6R7. R2 is —OR5, halogen, —NR6R7, —N+HR6R7 X− sulphonic acid, nitro, —NR5COOR5, —NR5COR5 or —OCOR5; R3 and R4 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; each R5 is independently —H or a C1-C4 alkyl group; R6 and R7 are independently H, C1-C4 alkyl group or, taken together with the nitrogen atom to which they are bonded, a non-aromatic nitrogen-containing heterocyclic group; n is an integer from 0-3; and X− is the carboxylate anion of an organic carboxylic acid compound. Also disclosed are methods of preparing certain compounds represented by Structural Formula (I).Type: GrantFiled: April 22, 2002Date of Patent: February 17, 2004Assignee: Xanthus Life Sciences, Inc.Inventors: Alfred M. Ajami, David O. Barlow
-
Publication number: 20030203932Abstract: Disclosed is a salt of amonafide or amonafide analogs represented Structural Formula (I): 1Type: ApplicationFiled: April 22, 2002Publication date: October 30, 2003Applicant: Xanthus Life Sciences, Inc.Inventors: Alfred M. Ajami, David O. Barlow
-
Publication number: 20030195350Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antiviral agents.Type: ApplicationFiled: November 27, 2002Publication date: October 16, 2003Applicant: Xanthus Life Sciences, IncInventor: Brian Leyland-Jones
-
Publication number: 20030185753Abstract: The invention relates to an enzyme linked immunosorbent assay (ELISA) method and kit for the rapid determination of metabolic phenotypes for Cytochrome P450 2C9 (CYP 2C9). The kit uses may include but are not limited to, use on a routine basis in a clinical laboratory to determine a Cytochrome P450 2C9 (CYP 2C9) phenotype of an individual; to allow a physician to individualize an individual's treatment with respect to the numerous drugs metabolized by CYP 2C9 based on a phenotypic determination; to predict an individual's susceptibility to carcinogen induced diseases including many cancers, and to screen individuals for a preferred metabolic phenotype in order to determine those individuals with a responsive phenotype for participation in clinical testing.Type: ApplicationFiled: December 19, 2002Publication date: October 2, 2003Applicant: Xanthus Life Sciences, Inc.Inventor: Brian Leyland-Jones
-
Publication number: 20030180823Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antihistamines.Type: ApplicationFiled: December 19, 2002Publication date: September 25, 2003Applicant: Xanthus Life Sciences, Inc.Inventor: Brian Leyland-Jones
-
Patent number: 6610270Abstract: It is an object of the present invention to provide in vivo analytical methods that allow for diagnosis and management of therapy for diseases involving discrete biochemical pathways. In the method of the invention, a labelled tracer probe, a specifically designed substrate of a “gateway” enzyme, an enzyme marking a regulatory point in a discrete biochemical pathway, is administered to a subject; a labelled product of the action of the enzyme is measured; and the appearance and concentration of the product are related to the disease condition of interest. Determination of the rate of substrate-product conversion of the gateway enzyme allows for the analysis to be made. The method involves administering a defined amount of a labelled “metaprobe” substrate of the gateway enzyme to a subject, at a site that provides access to a desired pool of the gateway enzyme in the subject, and measuring the amount of the chosen labelled product.Type: GrantFiled: December 18, 2000Date of Patent: August 26, 2003Assignee: Xanthus Life Sciences, Inc.Inventor: Alfred M. Ajami
-
Publication number: 20030073743Abstract: A therapeutic composition comprising an alkyl, aralkyl, alkoxyalkyl or carboxyalkyl ester of 2-ketoalkanoic acid and a component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is disclosed. The composition of the invention further comprises a pharmceutically acceptable carier vehicle in which the enol resonance form of the ester is stabilized at physiological pH values. Formulations containing the compositions of the invention permit the successful use of 2-ketoalkanoic acid esters, e.g., pyruvic acid esters, to treat, e.g., ischemic events, shock, organ reanimation, resuscitation and other recognized pyruvate-effective treatments. The compositions of the inventions are also useful in a process for preserving organ parts, organs or limbs removed from a living mammal and in need of preservation, e.g., for later transplantation to an organ recipient.Type: ApplicationFiled: April 4, 2002Publication date: April 17, 2003Applicant: Xanthus Life Sciences, Inc.Inventors: Alfred M. Ajami, Carrie A. Sims, Mitchell P. Fink